Compounds / Cognitive / Orexin-B

Orexin-B

Orexin-B (Hypocretin-2, OxB — Wakefulness Neuropeptide)

CognitiveFDA: Not approved — orexin agonists...

Overview

Discovered 1998. Orexin neuron loss is the established cause of narcolepsy type 1. Orexin receptor antagonists (suvorexant) are FDA-approved insomnia drugs, validating the pathway. Intranasal orexin-A restores wakefulness in narcoleptic primates.

Mechanism of Action

Endogenous neuropeptide binding OX1R/OX2R (10x selectivity for OX2R). Activates wake-promoting centers (locus coeruleus, TMN, raphe). Regulates wakefulness, arousal, appetite, reward. Orexin neuron loss causes narcolepsy type 1.

Molecular Profile

Molecular weight

2937.4 Da

CAS number

205640-90-0

Key Research Findings

Discovered 1998; narcolepsy type 1 caused by orexin loss; less stable than Orexin-A; OX2R selective; orexin agonists in clinical trials for narcolepsy.

Published Research

Cell

Orexins: a family of hypothalamic neuropeptides

View source

Nature Medicine

Narcolepsy caused by loss of orexin neurons

View source

Related Cognitive Compounds

Semax NA Semax Amidate Selank Adalank Adamax Dihexa

Clinical Guidance

Research data is not a treatment plan. If you are considering Orexin-B, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running Orexin-B? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals